查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2139043

長效注射劑市場：依技術、持續時間、適應症、給藥途徑及最終用戶分類－市場規模、產業趨勢、機會分析及2026-2035年預測

Long-Acting Injectable Therapeutics Market By Technology, Duration, Indication, Route, End User - Market Size, Industry Dynamics, Opportunity Analysis and Forecast For 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 280 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球長效注射療法市場呈現強勁的銷售成長勢頭，反映出人們對能夠長期持續給藥的治療方案的需求日益成長。預計到2025年，該市場規模將達到約140億美元，顯示長效製劑在眾多治療領域中日益重要的商業性價值。

預計未來十年市場將顯著擴張，到2035年將達到約450億美元。 2026年至2035年，市場預計將以12.4%的複合年成長率成長。這代表著市場規模的大幅擴張，凸顯了長效注射療法技術在藥物治療中日益重要的角色。

顯著的市場趨勢

長效注射劑市場的競爭格局主要由多家製藥公司所構成，這些公司擁有涵蓋精神科、感染疾病、成癮治療、腫瘤學、循環系統疾病及其他治療領域的成熟產品系列。主要參與企業包括強生公司、葛蘭素史克（透過其子公司ViiV Healthcare）、大塚製藥、Alkermes和諾華公司。

這些公司展現了長效注射療法市場競爭的激烈程度。它們的產品系列涵蓋多種治療領域，採用不同的緩釋給藥方式，包括長效型抗精神病藥物、長效抗逆轉錄病毒注射、用於治療物質使用障礙的緩釋製劑以及低頻皮下注射療法。隨著製藥公司尋求擴大長效療法的臨床應用和商業性覆蓋範圍，持續開發延長給藥間隔、替代給藥途徑、特殊製劑以及以患者為中心的給藥系統預計將仍將是競爭的關鍵要素。

主要成長要素

對長效注射療法的需求日益成長，這與解決藥物疲勞和治療依從性問題密切相關，尤其是在慢性病或終身疾病患者中。傳統的口服療法通常要求患者長期堅持每日服藥，有時甚至需要服用多種藥物，每天多次給藥。隨著時間的推移，這種持續的用藥要求會成為一種負擔，可能導致漏服、延遲服藥或服藥不規則。長效注射療法透過延長給藥間隔，減少患者需要主動記住和遵循服藥計劃的頻率，為解決這些難題提供了替代方案。

新機會的趨勢

在長效注射劑市場，從肌肉注射（IM）到皮下注射（SC）的轉變正成為一項重要的成長機會。雖然肌肉注射傳統上廣泛用於緩釋製劑和長效緩釋製劑，但藥物研發正日益關注皮下給藥系統，該系統有望提供更便捷的給藥體驗，同時實現藥物的持續釋放。製劑技術、給藥裝置和緩釋機制的進步推動了這一轉變，使得藥物能夠有效地透過皮下組織遞送。

最佳化障礙

生產流程的複雜性和高昂的生產成本可能成為限制長效注射劑市場成長的主要因素。與傳統的口服製劑不同，長效注射劑通常需要先進的藥物遞送技術、專門的生產流程和嚴格的品管程序。緩釋製劑、微球、懸浮液和其他緩釋系統的研發和生產可能涉及多個加工步驟，這使得生產過程在技術上更加複雜，也更加耗費資源。

目錄

第1章：摘要整理

  • 全球長效注射療法市場

第2章：調查方法與研究框架

  • 研究目標
  • 產品概述
  • 市場區隔
  • 定性研究
    • 主要訊息
    • 二手資訊
  • 量化研究
    • 主要訊息
    • 次要訊息
  • 主要調查受訪者組成：按地區分類
  • 本研究的前提
  • 市場規模估算
  • 數據三角測量

第3章：全球長效注射治療藥物市場概覽

  • 產業價值鏈分析
  • 產業展望
    • 全球長效注射劑（LAI）治療產業概覽
    • 解決藥物依從性和「藥物疲勞」問題正在推動長效注射劑在精神病學、HIV PrEP/ART 和代謝疾病領域的應用。
    • 超長效製劑（每年兩次注射來那卡帕韋）、從肌肉注射過渡到皮下自我給藥、PLGA/AI-QbD 聚合物工程、第三季度生物等效性導致學名藥進入市場障礙，以及每月一次注射的基於 GLP-1 的長效注射療法 (LAI) 產品線。
  • PESTLE分析
  • 波特五力分析
  • 市場成長及前景
    • 2020-2035年市場收入估算與預測
    • 價格趨勢分析：依技術分類

第4章：全球長效注射治療藥物市場分析

  • 競爭對手儀表板
    • 市場集中度
    • 企業市場占有率分析，2025 年
    • 競爭對手分析與基準測試

第5章：全球長效注射治療藥物市場分析

  • 市場動態和趨勢
    • 成長要素
    • 抑制因子
    • 機會
    • 主要趨勢
  • 市場規模及預測，2020-2035年
    • 透過技術
      • 關鍵見解
        • 聚合物微球
        • 原位成型凝膠/儲庫
        • 結晶質懸浮液
        • 植入
        • 脂質緩釋製劑
    • 時期
      • 關鍵見解
        • 每週/每月
        • 季刊
        • 超過6個月
    • 適應症
      • 關鍵見解
        • 精神病學（思覺失調症、躁鬱症）
        • 愛滋病毒治療與預防
        • 腫瘤學和荷爾蒙療法
        • 物質使用障礙
        • 代謝性疾病/肥胖症
        • 眼科
    • 路線
      • 關鍵見解
        • 肌肉內部
        • 皮下
        • 眼內/局部
    • 最終用戶
      • 關鍵見解
        • 醫院
        • 專科診所
        • 居家醫療和社區醫療
    • 按地區
      • 關鍵見解
        • 北美洲
          • 美國
          • 加拿大
          • 墨西哥
        • 歐洲
          • 西歐
            • 英國
            • 德國
            • 法國
            • 義大利
            • 西班牙
            • 其他西歐國家
          • 東歐
            • 波蘭
            • 俄羅斯
            • 其他東歐國家
        • 亞太地區
          • 中國
          • 印度
          • 日本
          • 澳洲和紐西蘭
          • 韓國
          • ASEAN
          • 其他亞太國家
        • 中東和非洲（MEA）
          • 沙烏地阿拉伯
          • 南非
          • UAE
          • 其他中東和非洲國家
        • 南美洲
          • 阿根廷
          • 巴西
          • 其他南美國家

第6章：北美市場分析

第7章：歐洲市場分析

第8章：亞太市場分析

第9章：中東和非洲市場分析

第10章：南美市場分析

第11章：公司簡介

公司簡介（公司概況、財務指標、主要產品清單、主要負責人、主要競爭對手、聯絡資訊和業務策略展望）

  • Johnson & Johnson
  • GSK (ViiV Healthcare)
  • Otsuka Pharmaceutical
  • Alkermes
  • Novartis
  • Gilead Sciences
  • Teva Pharmaceuticals
  • Medincell
  • Lupin
  • Amneal Pharmaceuticals
  • Daewoong Pharmaceutical
  • Lundbeck
  • 其他主要公司

第12章附錄

簡介目錄
Product Code: AA09261986

The global long-acting injectable therapeutics market is experiencing strong revenue growth, reflecting increasing demand for treatment options that can provide sustained drug delivery over extended periods. The market is estimated to be valued at approximately USD 14 billion in 2025, indicating the growing commercial importance of long-acting formulations across a range of therapeutic applications.

The market is projected to expand substantially over the coming decade, reaching an estimated value of USD 45 billion by 2035. Between 2026 and 2035, the market is projected to grow at a compound annual growth rate (CAGR) of 12.4%. This represents a significant increase in market size and highlights the expanding role of long-acting injectable technologies in pharmaceutical treatment.

Noteworthy Market Developments

The competitive landscape of the long-acting injectable therapeutics market includes several pharmaceutical companies with established portfolios spanning psychiatry, infectious diseases, addiction treatment, oncology, cardiovascular care, and other therapeutic areas. Among the prominent participants are Johnson & Johnson, GSK through ViiV Healthcare, Otsuka Pharmaceutical, Alkermes, and Novartis.

These companies illustrate the breadth of competition within the long-acting injectable therapeutics market. Their portfolios cover different therapeutic areas and employ different approaches to sustained drug delivery, including depot antipsychotics, long-acting antiretroviral injections, extended-release formulations for substance-use disorders, and subcutaneous therapies designed for infrequent administration. Continued development of longer dosing intervals, alternative injection routes, specialized formulations, and patient-oriented delivery systems is likely to remain an important component of competition as pharmaceutical companies seek to expand the clinical applications and commercial reach of long-acting therapeutics.

Core Growth Drivers

The growing demand for long-acting injectable therapies is strongly associated with the need to address medication fatigue and challenges with treatment adherence, particularly among patients managing chronic and lifelong conditions. Conventional oral therapies often require patients to follow a daily medication schedule over extended periods, sometimes involving multiple medicines and multiple doses each day. Over time, this continuous requirement can become burdensome and may contribute to missed, delayed, or inconsistent doses. Long-acting injectable formulations provide an alternative approach by extending the interval between administrations and reducing the frequency with which patients need to actively remember and take medication.

Emerging Opportunity Trends

The shift from intramuscular (IM) to subcutaneous (SC) delivery is emerging as an important opportunity for growth in the long-acting injectable therapeutics market. While intramuscular administration has traditionally been widely used for depot and sustained-release formulations, pharmaceutical development is increasingly exploring subcutaneous delivery systems that can provide prolonged drug release while potentially offering a more convenient administration experience. This transition is being supported by advances in formulation technologies, drug-delivery devices, and sustained-release mechanisms that enable therapeutic agents to be delivered effectively through the subcutaneous tissue.

Barriers to Optimization

High manufacturing complexity and elevated production costs may act as significant restraints on the growth of the long-acting injectable therapeutics market. Unlike conventional oral formulations, long-acting injectable products often require sophisticated drug-delivery technologies, specialized manufacturing processes, and stringent quality-control procedures. The development and production of depot formulations, microspheres, suspensions, and other sustained-release systems can involve multiple processing stages, making manufacturing more technically demanding and resource-intensive.

Detailed Market Segmentation

By duration, the weekly-to-monthly sub-segment accounted for the largest share of the market in 2025, supported by the growing adoption of long-acting therapies designed to maintain therapeutic drug exposure over extended intervals. Formulations administered on a weekly or monthly basis provide an intermediate balance between treatment frequency and sustained drug delivery. Compared with therapies requiring daily administration, these regimens can reduce the number of dosing occasions while still allowing healthcare professionals to monitor treatment progress at regular intervals.

By indication, psychiatry, particularly the treatment of schizophrenia and bipolar disorder, accounted for the largest share of the market in 2025. The strong position of this segment is closely associated with the importance of maintaining consistent treatment over prolonged periods in patients with chronic psychiatric conditions. Long-term pharmacological management is often an important component of preventing symptom recurrence and supporting disease stability. Consequently, therapeutic approaches that can provide sustained drug exposure and reduce interruptions in treatment have attracted significant attention within the psychiatric care landscape.

By route of administration, intramuscular administration emerged as the dominant route in the long-acting injectable therapeutics market during 2025. Its widespread adoption can be attributed to its suitability for delivering formulations designed to release active pharmaceutical ingredients gradually over an extended period. Intramuscular injections allow long-acting formulations to be deposited directly into muscle tissue, where the medication can form a depot and subsequently be released into systemic circulation in a controlled manner. This characteristic makes the route particularly appropriate for depot suspensions, polymer-based microspheres, and other formulations intended to provide prolonged therapeutic effects.

By end user, hospitals are expected to account for the largest share of the market in 2025, reflecting their central role in the administration and clinical management of depot injections. Hospitals serve as the primary point of care for patients receiving these treatments, particularly during the initial stages of therapy when close medical supervision is often required. The controlled environment of hospital settings allows healthcare professionals to assess patients before administration, ensure appropriate dosing, observe treatment responses, and address any immediate complications or adverse reactions that may occur following the injection.

Segment Breakdown

By Technology

  • Polymeric Microspheres
  • In-Situ Forming Gels/Depots
  • Crystalline Suspensions
  • Implants
  • Lipid-Based Depots

By Duration

  • Weekly-Monthly
  • Quarterly
  • Six-Month and Longer

By Indication

  • Psychiatry (Schizophrenia, Bipolar)
  • HIV Treatment & Prevention
  • Oncology & Hormonal
  • Substance Use Disorder
  • Metabolic/Obesity
  • Ophthalmology

By Route

  • Intramuscular
  • Subcutaneous
  • Intraocular/Local

By End User

  • Hospitals
  • Specialty Clinics
  • Homecare & Community Health

By Region

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa (MEA)
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
  • South America
  • Argentina
  • Brazil
  • Rest of South America
  • Geography Analysis
  • North America commands the apex position as the dominant region in the long-acting injectable therapeutics market, capturing over 45% of global revenue. This undeniable stronghold is propelled by the early commercialization of advanced depot formulations and highly structured reimbursement frameworks under major public healthcare initiatives like Medicare and Medicaid, which facilitate steady clinical adoption and market penetration.
  • The United States unequivocally anchors this regional dominance, contributing an estimated 85% of total sales through its advanced healthcare infrastructure and high patient demand for optimized chronic care management. Within this ecosystem, US-based pharmaceutical giants continuously channel heavy investments exceeding USD 2 billion into next-generation polymer matrices and microsphere technologies, specifically targeting enhanced delivery mechanisms for psychiatric and endocrine applications.
  • Meanwhile, Canada further bolsters regional growth by systematically integrating these sustained-release therapies into provincial mental health programs. By streamlining access to extended-release medications, the Canadian healthcare system effectively mitigates high hospital readmission rates, ensuring long-term therapeutic compliance and optimizing outpatient care outcomes across provinces.

Table of Content

Chapter 1. Executive Summary

  • 1.1. Global Long-Acting Injectable Therapeutics Market

Chapter 2. Research Methodology & Research Framework

  • 2.1. Research Objective
  • 2.2. Product Overview
  • 2.3. Market Segmentation
  • 2.4. Qualitative Research
    • 2.4.1. Primary Sources
    • 2.4.2. Secondary Sources
  • 2.5. Quantitative Research
    • 2.5.1. Primary Sources
    • 2.5.2. Secondary Sources
  • 2.6. Breakdown of Primary Research Respondents, By Region
  • 2.7. Assumption for Study
  • 2.8. Market Size Estimation
  • 2.9. Data Triangulation

Chapter 3. Global Long-Acting Injectable Therapeutics Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. PLGA Polymer/Biomaterial & API Suppliers
    • 3.1.2. LAI Formulation (Microsphere, In-Situ Gel, Crystalline Suspension, Implant) Developers
    • 3.1.3. Sterile Fill-Finish, Device (Prefilled Syringe/Autoinjector) & Cold-Chain Manufacturing
    • 3.1.4. Clinical Development, Regulatory (Q3 Bioequivalence) & Payer Partners
    • 3.1.5. End Users (Hospitals, Specialty Clinics, Homecare & Community Health)
  • 3.2. Industry Outlook
    • 3.2.1. Overview of the Global Long-Acting Injectable (LAI) Therapeutics Industry
    • 3.2.2. Adherence / "Pill Fatigue" Solution Driving LAI Adoption in Psychiatry, HIV PrEP/ART & Metabolic Disease
    • 3.2.3. Ultra-Long-Acting (Biannual Lenacapavir), IM-to-Subcutaneous Self-Administration Shift, PLGA/AI-QbD Polymer Engineering, Q3-Bioequivalence Generic Barrier & GLP-1 Monthly LAI Pipeline
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of New Entrants
    • 3.4.4. Threat of Substitutes
    • 3.4.5. Intensity of Rivalry
  • 3.5. Market Growth and Outlook
    • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
    • 3.5.2. Price Trend Analysis, By Technology

Chapter 4. Global Long-Acting Injectable Therapeutics Market Analysis

  • 4.1. Competition Dashboard
    • 4.1.1. Market Concentration Rate
    • 4.1.2. Company Market Share Analysis (Value %), 2025
    • 4.1.3. Competitor Mapping & Benchmarking

Chapter 5. Global Long-Acting Injectable Therapeutics Market Analysis

  • 5.1. Market Dynamics and Trends
    • 5.1.1. Growth Drivers
    • 5.1.2. Restraints
    • 5.1.3. Opportunity
    • 5.1.4. Key Trends
  • 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.2.1. By Technology
      • 5.2.1.1. Key Insights
        • 5.2.1.1.1. Polymeric Microspheres
        • 5.2.1.1.2. In-Situ Forming Gels/Depots
        • 5.2.1.1.3. Crystalline Suspensions
        • 5.2.1.1.4. Implants
        • 5.2.1.1.5. Lipid-Based Depots
    • 5.2.2. By Duration
      • 5.2.2.1. Key Insights
        • 5.2.2.1.1. Weekly-Monthly
        • 5.2.2.1.2. Quarterly
        • 5.2.2.1.3. Six-Month and Longer
    • 5.2.3. By Indication
      • 5.2.3.1. Key Insights
        • 5.2.3.1.1. Psychiatry (Schizophrenia, Bipolar)
        • 5.2.3.1.2. HIV Treatment & Prevention
        • 5.2.3.1.3. Oncology & Hormonal
        • 5.2.3.1.4. Substance Use Disorder
        • 5.2.3.1.5. Metabolic/Obesity
        • 5.2.3.1.6. Ophthalmology
    • 5.2.4. By Route
      • 5.2.4.1. Key Insights
        • 5.2.4.1.1. Intramuscular
        • 5.2.4.1.2. Subcutaneous
        • 5.2.4.1.3. Intraocular/Local
    • 5.2.5. By End User
      • 5.2.5.1. Key Insights
        • 5.2.5.1.1. Hospitals
        • 5.2.5.1.2. Specialty Clinics
        • 5.2.5.1.3. Homecare & Community Health
    • 5.2.6. By Region
      • 5.2.6.1. Key Insights
        • 5.2.6.1.1. North America
          • 5.2.6.1.1.1. The U.S.
          • 5.2.6.1.1.2. Canada
          • 5.2.6.1.1.3. Mexico
        • 5.2.6.1.2. Europe
          • 5.2.6.1.2.1. Western Europe
            • 5.2.6.1.2.1.1. The UK
            • 5.2.6.1.2.1.2. Germany
            • 5.2.6.1.2.1.3. France
            • 5.2.6.1.2.1.4. Italy
            • 5.2.6.1.2.1.5. Spain
            • 5.2.6.1.2.1.6. Rest of Western Europe
          • 5.2.6.1.2.2. Eastern Europe
            • 5.2.6.1.2.2.1. Poland
            • 5.2.6.1.2.2.2. Russia
            • 5.2.6.1.2.2.3. Rest of Eastern Europe
        • 5.2.6.1.3. Asia Pacific
          • 5.2.6.1.3.1. China
          • 5.2.6.1.3.2. India
          • 5.2.6.1.3.3. Japan
          • 5.2.6.1.3.4. Australia & New Zealand
          • 5.2.6.1.3.5. South Korea
          • 5.2.6.1.3.6. ASEAN
          • 5.2.6.1.3.7. Rest of Asia Pacific
        • 5.2.6.1.4. Middle East & Africa (MEA)
          • 5.2.6.1.4.1. Saudi Arabia
          • 5.2.6.1.4.2. South Africa
          • 5.2.6.1.4.3. UAE
          • 5.2.6.1.4.4. Rest of MEA
        • 5.2.6.1.5. South America
          • 5.2.6.1.5.1. Argentina
          • 5.2.6.1.5.2. Brazil
          • 5.2.6.1.5.3. Rest of South America

Chapter 6. North America Market Analysis

  • 6.1. Market Dynamics and Trends
    • 6.1.1. Growth Drivers
    • 6.1.2. Restraints
    • 6.1.3. Opportunity
    • 6.1.4. Key Trends
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 6.2.1. Key Insights
      • 6.2.1.1. By Technology
      • 6.2.1.2. By Duration
      • 6.2.1.3. By Indication
      • 6.2.1.4. By Route
      • 6.2.1.5. By End User
      • 6.2.1.6. By Country

Chapter 7. Europe Market Analysis

  • 7.1. Market Dynamics and Trends
    • 7.1.1. Growth Drivers
    • 7.1.2. Restraints
    • 7.1.3. Opportunity
    • 7.1.4. Key Trends
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 7.2.1. Key Insights
      • 7.2.1.1. By Technology
      • 7.2.1.2. By Duration
      • 7.2.1.3. By Indication
      • 7.2.1.4. By Route
      • 7.2.1.5. By End User
      • 7.2.1.6. By Country

Chapter 8. Asia Pacific Market Analysis

  • 8.1. Market Dynamics and Trends
    • 8.1.1. Growth Drivers
    • 8.1.2. Restraints
    • 8.1.3. Opportunity
    • 8.1.4. Key Trends
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 8.2.1. Key Insights
      • 8.2.1.1. By Technology
      • 8.2.1.2. By Duration
      • 8.2.1.3. By Indication
      • 8.2.1.4. By Route
      • 8.2.1.5. By End User
      • 8.2.1.6. By Country

Chapter 9. Middle East & Africa (MEA) Market Analysis

  • 9.1. Market Dynamics and Trends
    • 9.1.1. Growth Drivers
    • 9.1.2. Restraints
    • 9.1.3. Opportunity
    • 9.1.4. Key Trends
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 9.2.1. Key Insights
      • 9.2.1.1. By Technology
      • 9.2.1.2. By Duration
      • 9.2.1.3. By Indication
      • 9.2.1.4. By Route
      • 9.2.1.5. By End User
      • 9.2.1.6. By Country

Chapter 10. South America Market Analysis

  • 10.1. Market Dynamics and Trends
    • 10.1.1. Growth Drivers
    • 10.1.2. Restraints
    • 10.1.3. Opportunity
    • 10.1.4. Key Trends
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 10.2.1. Key Insights
      • 10.2.1.1. By Technology
      • 10.2.1.2. By Duration
      • 10.2.1.3. By Indication
      • 10.2.1.4. By Route
      • 10.2.1.5. By End User
      • 10.2.1.6. By Country

Chapter 11. Company Profile

Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 11.1. Johnson & Johnson
  • 11.2. GSK (ViiV Healthcare)
  • 11.3. Otsuka Pharmaceutical
  • 11.4. Alkermes
  • 11.5. Novartis
  • 11.6. Gilead Sciences
  • 11.7. Teva Pharmaceuticals
  • 11.8. Medincell
  • 11.9. Lupin
  • 11.10. Amneal Pharmaceuticals
  • 11.11. Daewoong Pharmaceutical
  • 11.12. Lundbeck
  • 11.13. Other Prominent Players

Chapter 12. Annexure

  • 12.1. List of Secondary Sources
  • 12.2. Key Country Markets- Macro Economic Outlook/Indicators